LG100617

LG617, also known as LG100617, is a potent and selective small-molecule antagonist of the Retinoid X Receptor (RXR), a member of the nuclear receptor superfamily. Developed by Ligand Pharmaceuticals, LG617 was designed to specifically inhibit the transcriptional activity of RXR, which serves as an essential heterodimeric partner for various other nuclear receptors, including the Retinoic Acid Receptor (RAR), Peroxisome Proliferator-Activated Receptors (PPARs), Vitamin D Receptor (VDR), and Thyroid Hormone Receptor (TR). By blocking the recruitment of co-activators and preventing the activation of RXR-containing heterodimers, LG617 has been extensively used as a pharmacological tool to dissect the complex signaling networks of nuclear receptors in preclinical models. Research has explored its potential applications in oncology, particularly in inhibiting the growth of certain breast cancer cell lines, and in metabolic research to understand the regulation of glucose and lipid metabolism. Despite its utility in research, LG617 has not progressed into clinical development.